OverviewSuggest Edit

Eidos Therapeutics is a biotech company developing novel, genetically targeted therapies to improve the lives of patients. The Company's approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
TypePublic
Founded2013
HQSan Francisco, US
Websiteeidostx.com

Latest Updates

Employees (est.) (Dec 2019)45(+13%)
Revenue (FY, 2019)$26.7 M
Share Price (Jun 2020)$49.5

Key People/Management at Eidos Therapeutics

Neil Kumar

Neil Kumar

Chief Executive Officer, Director
Jonathan Fox

Jonathan Fox

President and Chief Medical Officer
Christine Siu

Christine Siu

Chief Financial Officer
Uma Sinha

Uma Sinha

Chief Scientific Officer, Director
Cameron Turtle

Cameron Turtle

Chief Business Officer
Isabella Graef

Isabella Graef

Scientific Co-Founder
Show more

Eidos Therapeutics Office Locations

Eidos Therapeutics has an office in San Francisco
San Francisco, US (HQ)
101 Montgomery St #2550, San Francisco
Show all (1)

Eidos Therapeutics Financials and Metrics

Eidos Therapeutics Revenue

Eidos Therapeutics's revenue was reported to be $26.69 m in FY, 2019
USD

Net income (Q1, 2020)

(22.8m)

EBIT (Q1, 2020)

(22.9m)

Market capitalization (3-Jun-2020)

1.9b

Closing stock price (3-Jun-2020)

49.5

Cash (31-Mar-2020)

196.5m

EV

4.7b
Eidos Therapeutics's current market capitalization is $1.9 b.
Annual
USDFY, 2018FY, 2019

Revenue

26.7m

Cost of goods sold

2.5m

Gross profit

24.2m

Gross profit Margin, %

91%
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

26.7m

Cost of goods sold

2.5m

Gross profit

24.2m

Gross profit Margin, %

91%
Annual
USDFY, 2018FY, 2019

Cash

157.1m191.2m

Prepaid Expenses

1.8m4.7m

Current Assets

159.0m195.9m

PP&E

209.0k1.3m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

176.7m166.6m147.1m131.4m165.8m196.5m

Prepaid Expenses

2.2m3.2m2.2m3.9m5.4m4.0m

Current Assets

179.0m169.8m149.3m135.5m171.3m200.6m

PP&E

219.0k218.0k196.0k204.0k1.2m1.3m
Annual
USDFY, 2018FY, 2019

Net Income

(40.7m)(37.8m)

Depreciation and Amortization

56.0k77.0k

Accounts Payable

1.4m1.2m

Cash From Operating Activities

(33.1m)(31.6m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(26.2m)(36.4m)(11.7m)(25.8m)(18.9m)(22.8m)

Depreciation and Amortization

24.0k40.0k15.0k33.0k53.0k27.0k

Accounts Payable

1.2m1.9m1.3m(114.0k)1.6m821.0k

Cash From Operating Activities

(14.8m)(23.7m)(10.1m)(26.1m)(15.1m)(18.9m)
USDY, 2020

EV/EBIT

-204.9 x

EV/CFO

-248.4 x

Financial Leverage

1.2 x
Show all financial metrics

Eidos Therapeutics Online and Social Media Presence

Embed Graph

Eidos Therapeutics News and Updates

Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent ach…

Eidos Therapeutics Reports Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an update on the company’s recent achievements.

Eidos Therapeutics Reports First Quarter 2019 Financial Results

SAN FRANCISCO, May 07, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company’s recent achievements.

Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results

Phase 3 study of AG10 in patients with ATTR-CM (ATTRIBUTE-CM) underway Phase 3 study of AG10 in patients with ATTR-CM (ATTRIBUTE-CM) underway

RM LAW Announces an Investigation of Eidos Therapeutics, Inc.

BERWYN, Pa., April 5, 2019 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Eidos Therapeutics, Inc. (NASDAQ: EIDX) ("Eidos Therapeutics" or the "Company") investors concerning the Company and its officers' possible violations of federal securities laws. If you...

Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions

AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM).
Show more

Eidos Therapeutics Blogs

Associate Director, Professional Services

The post Associate Director, Professional Services appeared first on Eidos Therapeutics.

Associate Director of Marketing

The post Associate Director of Marketing appeared first on Eidos Therapeutics.

Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference Content Import Thu, 09/19/2019 - 08:01 Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference September 19, 2019 at 8:00 AM EDT This release is a backfill from…

Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares

Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time SAN FRANCISCO --(BUSINESS WIRE)--Aug. 12, 2019-- Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal

Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference

Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference Content Import Tue, 06/18/2019 - 08:01 Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference June 18, 2019 at 8:00 AM EDT This…

Eidos Therapeutics to Present at 31st Annual ROTH Conference

Eidos Therapeutics to Present at 31st Annual ROTH Conference Content Import Mon, 03/11/2019 - 08:09 Eidos Therapeutics to Present at 31st Annual ROTH Conference March 11, 2019 at 4:00 AM EDT This release is a backfill from a News Wire General …
Show more

Eidos Therapeutics Frequently Asked Questions

  • When was Eidos Therapeutics founded?

    Eidos Therapeutics was founded in 2013.

  • Who are Eidos Therapeutics key executives?

    Eidos Therapeutics's key executives are Neil Kumar, Jonathan Fox and Christine Siu.

  • How many employees does Eidos Therapeutics have?

    Eidos Therapeutics has 45 employees.

  • What is Eidos Therapeutics revenue?

    Latest Eidos Therapeutics annual revenue is $26.7 m.

  • What is Eidos Therapeutics revenue per employee?

    Latest Eidos Therapeutics revenue per employee is $593.1 k.

  • Who are Eidos Therapeutics competitors?

    Competitors of Eidos Therapeutics include Vertex Pharmaceuticals, Alimera Sciences and JanOne.

  • Where is Eidos Therapeutics headquarters?

    Eidos Therapeutics headquarters is located at 101 Montgomery St #2550, San Francisco, San Francisco.

  • Where are Eidos Therapeutics offices?

    Eidos Therapeutics has an office in San Francisco.

  • How many offices does Eidos Therapeutics have?

    Eidos Therapeutics has 1 office.